India has cancelled the patent for Novartis’ heart failure drug Vymada, a move that opens the door for domestic pharmaceutical companies to launch low-cost generic versions. The decision is seen as a major step toward improving the affordability and accessibility of critical heart medication in the Indian market, where cost often limits patient access. With generics expected to enter soon, patients could benefit from significant price reductions, while local drug makers gain new market opportunities. The ruling also highlights India’s pro-generic patent policy, aimed at balancing innovation with public health needs.

https://analystip.com/novartis....-vymada-patent-revok